CA
ADPT icon

CoreCap Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

CoreCap Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$601 Hold
28
– – ﹤0.01% 2816
2026
Q1 		$389 Sell
28
-332
-92% -$5.29K ﹤0.01% 2689
2025
Q4 		$5.85K Sell
360
-53
-13% -$865 ﹤0.01% 2150
2025
Q3 		$6.18K Buy
413
+385
+1,375% +$4.69K ﹤0.01% 2116
2025
Q2 		$326 Hold
28
– – ﹤0.01% 2568
2025
Q1 		$208 Hold
28
– – ﹤0.01% 2959
2024
Q4 		$168 Hold
28
– – ﹤0.01% 2740
2024
Q3 		$143 Hold
28
– – ﹤0.01% 2534
2024
Q2 		$101 Hold
28
– – ﹤0.01% 1535
2024
Q1 		$90 Buy
+28
New +$108 ﹤0.01% 2450

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CoreCap Advisors's ADPT Position: Q2 2026 in Review

CoreCap Advisors held its Adaptive Biotechnologies (ADPT) position steady in Q2 2026 at 28 shares worth $601. The position accounts for ﹤0.01% of the portfolio, ranked #2816.

CoreCap Advisors first reported a position in ADPT in Q1 2024 and has held it in 10 quarters since. The position peaked at $6.18K in Q3 2025. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • CoreCap Advisors held 28 shares of Adaptive Biotechnologies worth $601 as of Q2 2026.
  • CoreCap Advisors left its Adaptive Biotechnologies share count unchanged in Q2 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2816 holding.
  • CoreCap Advisors first reported a position in Adaptive Biotechnologies in Q1 2024 and has held it in 10 quarters since.
  • CoreCap Advisors's Adaptive Biotechnologies position peaked at $6.18K in Q3 2025.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.